Eagle Pharma, Teva Pharma Win Patent Decision for Bendeka

By Chris Wack

Eagle Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. said Tuesday the U.S. District Court for the District of Delaware issued a favorable patent decision for Bendeka bendamustine hydrochloride injection, or bendamustine HCl, a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride.

The companies said the court upheld the asserted patent claims as valid and found that the defendants' proposed ANDA products would infringe on the claims.

Under the decision, the patent defendants--Slayback Pharma LLC, Apotex Inc. and Apotex Corp., Fresenius Kabi USA, LLC, and Mylan Laboratories Limited--won't be able to launch their ANDA products before 2031.

Eagle Pharmaceuticals shares rose 23% to $63.25 in premarket trading. Teva shares rose 2% to $10.88 premarket.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

April 28, 2020 08:29 ET (12:29 GMT)

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024